BioCentury
ARTICLE | Company News

Takeda cardiovascular news

November 17, 2014 8:00 AM UTC

Takeda announced new measures and disciplinary action as a result of inappropriate promotional activities utilizing results of the investigator-initiated Phase III CASE-J trial of Takeda's hypertension drug Blopress candesartan cilexetil. To prevent recurrences of such activities, Takeda said it will establish stricter review and management systems related to promotional activities; promote the Japan Pharmaceutical Manufacturer's Association (JPMA) Code of Practice (COP); strengthen measures to report adverse events; remove involvement of the marketing division in investigator-initiated sponsored research (IISR); develop and adhere to a procedure manual for IISR; and handle donations stricter to eliminate conflicts of interests and legal risks. Additionally, directors involved in the activities will have their monthly pay reduced by 5-20% for three months depending on their individual scope of responsibility and involved employees will be formally reprimanded. ...